Premium
Hormonal Cytoreduction and Radiotherapy for Carcinoma of the Prostate
Author(s) -
SHEARER R. J.,
DAVIES J. H.,
GELISTER J. S. K.,
DEARNALEY D. P.
Publication year - 1992
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1992.tb15601.x
Subject(s) - medicine , prostate , radiation therapy , goserelin , hormone , urology , external beam radiotherapy , prostate cancer , reduction (mathematics) , adverse effect , carcinoma , oncology , hormonal therapy , cancer , geometry , mathematics
Summary— We report the effect on prostatic volume of the administration of the luteinising hormone‐releasing hormone (LHRH) analogue goserelin in 22 patients with locally advanced carcinoma of the prostate; 20 achieved a significant reduction in volume, the median volume being 66 ml before treatment (range 40–130) and 30 ml after 17 weeks (range 13–47). If used before external beam radiotherapy (RT), volume reduction will permit smaller boost fields and thus potentially reduce adverse radiotherapy effects. In addition, reducing tumour volume before RT may lead to an increase in local control. We discuss the possible role of hormonal volume reduction in the management of prostatic cancer.